Jason M. Broderick

Data from the EMERALD-3 trial may position the STRIDE regimen with or without lenvatinib as a compelling therapeutic option in this HCC population.

A review of top ASCO abstracts with the potential to change everyday oncology practice.

"DISC-0974 treatment resulted in sustained hepcidin and serum iron, regardless of concomitant JAKi therapy or baseline transfusion requirement,” said Naseema Gangat, MBBS.

FDA accepted a priority-review sBLA for atezolizumab (IV or SC with hyaluronidase) plus mFOLFOX6 as adjuvant therapy after R0 resection in stage III dMMR/MSI-H colon cancer. ATOMIC showed 3-year DFS 86.3% vs 76.2% (HR 0.50), with consistency across nodal, T-stage, and location strata; findings held in per-protocol and centrally confirmed dMMR analyses.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

The FDA concurrently cleared the VENTANA PTEN (SP218) RxDx assay as a companion diagnostic to identify eligible patients.

Three-year failure-free survival met noninferiority for carboplatin vs cisplatin (84.8% vs 86.8%; HR 1.15), with similar event rates and consistent per-protocol findings. Overall survival and disease-control end points aligned between arms, with 3-year OS 96%–97%, DMFS ~90%, and locoregional failure-free survival exceeding 90%.

B7-H4, highly expressed in many endometrial/ovarian tumors with minimal normal-tissue expression, enables selective ADC delivery and underpins the therapeutic rationale for AZD8205. Dose-dependent efficacy favored 2.4 mg/kg, achieving endometrial ORR 47.1%, 12-week DCR 84.3%, median DOR 7.1 months, and median PFS 7.2 months.

The patients with HNSCC had already been treated with immune checkpoint inhibitors and platinum-based chemotherapy.

An ongoing dose expansion phase of the trial is evaluating CRB-701 plus pembrolizumab for first-line OPSCC.